• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

乙型肝炎病毒携带者自发乙型肝炎表面抗原血清学清除后乙型肝炎病毒血症的流行情况和危险因素。

Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers.

机构信息

Liver Research Unit, Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan.

出版信息

Clin Infect Dis. 2012 Jan 1;54(1):88-90. doi: 10.1093/cid/cir755. Epub 2011 Nov 3.

DOI:10.1093/cid/cir755
PMID:22052888
Abstract

In 118 previous hepatitis B surface antigen (HBsAg) carriers, low-level hepatitis B (HBV) viremia persisted at a rate of 15%-20% for >10 years after HBsAg seroclearance. The frequency of HBV viremia was significantly (P = .002) lower in patients with anti-HBsAg seroconversion (6 of 69 [8.7%]) than in those without seroconversion (15 of 49 [30.6%]).

摘要

在 118 名既往乙肝表面抗原(HBsAg)携带者中,HBsAg 血清学清除后 >10 年,低水平乙型肝炎病毒(HBV)血症的持续率为 15%-20%。HBsAg 血清转换患者(69 例中有 6 例 [8.7%])的 HBV 血症发生率显著(P=.002)低于未发生血清转换患者(49 例中有 15 例 [30.6%])。

相似文献

1
Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers.乙型肝炎病毒携带者自发乙型肝炎表面抗原血清学清除后乙型肝炎病毒血症的流行情况和危险因素。
Clin Infect Dis. 2012 Jan 1;54(1):88-90. doi: 10.1093/cid/cir755. Epub 2011 Nov 3.
2
Quantification of hepatitis B surface antigen can help predict spontaneous hepatitis B surface antigen seroclearance.乙肝表面抗原定量有助于预测乙肝表面抗原自发血清学清除。
Eur J Gastroenterol Hepatol. 2012 Apr;24(4):414-8. doi: 10.1097/MEG.0b013e328350594d.
3
Incidence and determinants of spontaneous hepatitis B surface antigen seroclearance: a community-based follow-up study.自发性乙型肝炎表面抗原血清学清除的发生率和决定因素:一项基于社区的随访研究。
Gastroenterology. 2010 Aug;139(2):474-82. doi: 10.1053/j.gastro.2010.04.048. Epub 2010 Apr 29.
4
HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up.高流行地区无症状携带者的HBsAg血清学清除:长期随访期间的显著高发生率
Hepatology. 2007 May;45(5):1187-92. doi: 10.1002/hep.21612.
5
Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age.HBsAg 血清学清除和死亡率在 HBsAg 流行率随年龄增长而下降中的相对作用。
Am J Gastroenterol. 2010 May;105(5):1102-9. doi: 10.1038/ajg.2009.669. Epub 2010 Mar 2.
6
Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B.慢性乙型肝炎患者乙肝表面抗原血清学清除后的长期预后
Am J Med. 2006 Jan;119(1):71.e9-16. doi: 10.1016/j.amjmed.2005.02.033.
7
Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany.德国抗HBe阳性乙型肝炎病毒携带者中前核心突变体的流行情况。
J Med Virol. 1999 Sep;59(1):14-8.
8
[Investigation of hemodialysis patients in terms of the presence of occult hepatitis B].[对血液透析患者隐匿性乙型肝炎感染情况的调查]
Mikrobiyol Bul. 2007 Apr;41(2):227-33.
9
Hepatitis B surface antigen seroclearance during chronic HBV infection.慢性乙型肝炎病毒感染期间的乙肝表面抗原血清清除
Antivir Ther. 2010;15(2):133-43. doi: 10.3851/IMP1497.
10
Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers.乙肝慢性携带者中HBsAg与抗-HBs抗体共存的临床及病毒学意义。
Virology. 2007 Oct 10;367(1):30-40. doi: 10.1016/j.virol.2007.05.012. Epub 2007 Jun 18.

引用本文的文献

1
Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens.基于聚乙二醇干扰素α方案诱导的乙型肝炎表面抗原血清学清除的复发和影响因素。
World J Gastroenterol. 2024 Nov 28;30(44):4725-4737. doi: 10.3748/wjg.v30.i44.4725.
2
Results of Nucleos(t)ide Analog Treatment Discontinuation in Hepatitis B e-Antigen-Negative Chronic Hepatitis B: NUCSTOP Study.核苷(酸)类似物停药治疗乙型肝炎 e 抗原阴性慢性乙型肝炎的结果:NUCSTOP 研究。
Turk J Gastroenterol. 2024 Jan;35(1):17-26. doi: 10.5152/tjg.2024.23463.
3
A comparative study of clinicopathological and imaging features of HBV-negative and HBV-positive intrahepatic cholangiocarcinoma patients with different pathologic differentiation degrees.
HBV 阴性和 HBV 阳性的不同病理分化程度的肝内胆管细胞癌患者的临床病理和影像学特征的对比研究。
Sci Rep. 2023 Nov 13;13(1):19726. doi: 10.1038/s41598-023-47108-6.
4
Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance.核苷(酸)类似物治疗慢性乙型肝炎患者 HBsAg 血清学清除后停药的临床结局。
J Gastroenterol. 2024 Jan;59(1):34-44. doi: 10.1007/s00535-023-02046-y. Epub 2023 Oct 14.
5
Guidelines for the Prevention and Treatment of Chronic Hepatitis B (version 2022).《慢性乙型肝炎防治指南(2022年版)》
J Clin Transl Hepatol. 2023 Nov 28;11(6):1425-1442. doi: 10.14218/JCTH.2023.00320. Epub 2023 Aug 15.
6
Lower end of treatment HBsAg and HBcrAg were associated with HBsAg loss after nucleos(t)ide analog cessation.治疗结束时 HBsAg 和 HBcrAg 下限与核苷(酸)类似物停药后 HBsAg 丢失相关。
BMC Gastroenterol. 2023 Jun 29;23(1):224. doi: 10.1186/s12876-023-02852-x.
7
Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens.短期聚乙二醇干扰素α-2b再治疗对基于聚乙二醇干扰素α方案停药后HBsAg复发患者诱导出高功能治愈率。
J Clin Med. 2023 Jan 2;12(1):361. doi: 10.3390/jcm12010361.
8
Study on the Retreatment, Outcome, and Potential Predictors of Recurrence in Patients With Recurrence of Hepatitis B After Functional Cure.乙型肝炎功能性治愈后复发患者再治疗、结局和复发潜在预测因素的研究。
Front Immunol. 2022 Jul 4;13:879835. doi: 10.3389/fimmu.2022.879835. eCollection 2022.
9
Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients.在 HBeAg 阳性慢性乙型肝炎患者中,干扰素-α诱导的 HBsAg 阴性持续应答需要巩固治疗。
Virol Sin. 2022 Jun;37(3):390-397. doi: 10.1016/j.virs.2022.03.001. Epub 2022 Mar 4.
10
Guidelines for Prevention and Treatment of Chronic Hepatitis B.慢性乙型肝炎防治指南
J Clin Transl Hepatol. 2021 Oct 28;9(5):769-791. doi: 10.14218/JCTH.2021.00209. Epub 2021 Sep 28.